A shift toward activated Treg subtypes was seen in patients with COVID-19 with increases in the activated CCR4+ (annotated as CCR4+), Helios–CCR6+ effectors, and several groups of proliferating Tregs (Fig. 3 C–E). Here, CCR4 is linked to COVID-19.